Teriparatide topical

Drug Profile

Teriparatide topical

Alternative Names: PTH (1-34); Topical PTH 1-34

Latest Information Update: 27 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IGI
  • Developer Manhattan Pharmaceuticals
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 31 May 2009 Teriparatide topical is no longer licensed to Manhattan Pharmaceuticals
  • 28 Dec 2005 Phase-II clinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top